The experimental HIV drug vicriviroc has stalled in development. The med, which blocks HIV from binding to CD4 cell CCR5 receptors, showed no added benefit when combined with other meds in studies among treatment-experienced people. Vicriviroc had been on track for FDA approval this year for treatment-experienced people with resistance to other HIV meds. But all is not lost: Vicriviroc trials continue among people new to meds.